All of the following are false about Tenapanor except:
Correct Answer: Constipation is a serious adverse effect
Description: Tenapanor Small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). MOA - Inhibitor of the sodium/hydrogen exchanger isoform 3 (NHE3) transpoer First and currently only medication within its class By inhibiting NHE3 on the apical surface of the enterocytes, tenapanor reduces absorption of sodium from the small intestine and colon, Resulting in an increase in water secretion into the intestinal lumen, which accelerates intestinal transit time and results in a softer stool consistency. Recommended dosage in adults - 50 mg orally twice daily- prior to breakfast or the first meal of the day and immediately prior to dinner C/I Patients< 6 years of age due to the risk of serious dehydration, Patients with known or suspected mechanical gastrointestinal obstruction
Category:
Pharmacology
Get More
Subject Mock Tests
Practice with over 200,000 questions from various medical subjects and improve your knowledge.
Attempt a mock test nowMock Exam
Take an exam with 100 random questions selected from all subjects to test your knowledge.
Coming SoonGet More
Subject Mock Tests
Try practicing mock tests with over 200,000 questions from various medical subjects.
Attempt a mock test now